# Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit

> **NCT00832650** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 60 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** fesoterodine fumarate
- **DRUG:** placebo
- **DRUG:** solifenacin

## Key facts

- **NCT ID:** NCT00832650
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Protocol A0221057 was terminated on December 25, 2009 for futility. There were no safety concerns related to this decision.
- **Last updated:** 2010-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00832650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00832650, "Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00832650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*